Repositioning Candidate Details
| Candidate ID: | R0264 |
| Source ID: | DB00915 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Amantadine |
| Synonyms: | |
| Molecular Formula: | C10H17N |
| SMILES: | NC12CC3CC(CC(C3)C1)C2 |
| Structure: |
|
| DrugBank Description: | An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. |
| CAS Number: | 768-94-5 |
| Molecular Weight: | 151.2487 |
| DrugBank Indication: | For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions. |
| DrugBank Pharmacology: | Amantadine is an antiviral drug which also acts as an antiparkinson agent, for which it is usually combined with L-DOPA when L-DOPA responses decline (probably due to tolerance). It is a derivate of adamantane, like a similar drug rimantadine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. It has been shown to cause an increase in dopamine release in the animal brain, and does not possess anticholinergic activity. |
| DrugBank MoA: | The mechanism of its antiparkinsonic effect is not fully understood, but it appears to be releasing dopamine from the nerve endings of the brain cells, together with stimulation of norepinephrine response. It also has NMDA receptor antagonistic effects. The antiviral mechanism seems to be unrelated. The drug interferes with a viral protein, M2 (an ion channel), which is needed for the viral particle to become "uncoated" once it is taken inside the cell by endocytosis. |
| Targets: | Matrix protein 2; Glutamate receptor ionotropic, NMDA 3A; Dopamine D2 receptor; Neuronal acetylcholine receptor subunit alpha-7; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit alpha-3 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|